Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
17 avr. 2018 09h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
16 avr. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
28 mars 2018 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 28, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results
21 mars 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
15 mars 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference
06 mars 2018 07h19 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
21 févr. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
06 févr. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference
24 janv. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018
09 janv. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) reviewed its 2017 achievements and provided an outline...